Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens, Wytske J. ; Lund, Valerie ; Bachert, Claus ; Mullol, Joaquim ; Bjermer, Leif LU ; Bousquet, Jean ; Canonica, Giorgio W. ; Deneyer, Lauren ; Desrosiers, Martin and Diamant, Zuzana LU , et al. (2019) In Allergy: European Journal of Allergy and Clinical Immunology 74(12). p.2312-2319
Abstract

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available... (More)

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
asthma, biologics, chronic rhinosinusitis, nasal polyps, type 2 inflammation
in
Allergy: European Journal of Allergy and Clinical Immunology
volume
74
issue
12
pages
2312 - 2319
publisher
Wiley-Blackwell
external identifiers
  • scopus:85069662686
  • pmid:31090937
ISSN
0105-4538
DOI
10.1111/all.13875
language
English
LU publication?
yes
id
c7649a7d-63ea-4869-b972-dc0f29467140
date added to LUP
2019-08-28 14:39:13
date last changed
2024-04-16 18:55:01
@article{c7649a7d-63ea-4869-b972-dc0f29467140,
  abstract     = {{<p>Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.</p>}},
  author       = {{Fokkens, Wytske J. and Lund, Valerie and Bachert, Claus and Mullol, Joaquim and Bjermer, Leif and Bousquet, Jean and Canonica, Giorgio W. and Deneyer, Lauren and Desrosiers, Martin and Diamant, Zuzana and Han, Joseph and Heffler, Enrico and Hopkins, Claire and Jankowski, Roger and Joos, Guy and Knill, Andrew and Lee, Jivianne and Lee, Stella E. and Mariën, Gert and Pugin, Benoit and Senior, Brent and Seys, Sven F. and Hellings, Peter W.}},
  issn         = {{0105-4538}},
  keywords     = {{asthma; biologics; chronic rhinosinusitis; nasal polyps; type 2 inflammation}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{2312--2319}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Allergy: European Journal of Allergy and Clinical Immunology}},
  title        = {{EUFOREA consensus on biologics for CRSwNP with or without asthma}},
  url          = {{http://dx.doi.org/10.1111/all.13875}},
  doi          = {{10.1111/all.13875}},
  volume       = {{74}},
  year         = {{2019}},
}